VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued on Sunday. The brokerage set a “sell” rating on the stock.

Other research analysts have also recently issued research reports about the company. D. Boral Capital reiterated a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research report on Monday, March 31st. HC Wainwright initiated coverage on shares of VolitionRx in a research note on Tuesday, April 8th. They issued a “buy” rating and a $2.50 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.33.

VolitionRx Stock Performance

Shares of VNRX opened at $0.50 on Friday. VolitionRx has a 52-week low of $0.42 and a 52-week high of $1.02. The firm has a market cap of $50.59 million, a price-to-earnings ratio of -1.39 and a beta of 1.15. The business’s fifty day moving average is $0.56 and its 200-day moving average is $0.62.

Insider Activity at VolitionRx

In other VolitionRx news, CEO Cameron John Reynolds bought 181,818 shares of the business’s stock in a transaction that occurred on Wednesday, March 26th. The shares were acquired at an average cost of $0.55 per share, for a total transaction of $99,999.90. Following the transaction, the chief executive officer now directly owns 2,299,222 shares in the company, valued at approximately $1,264,572.10. This represents a 8.59 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On VolitionRx

Large investors have recently modified their holdings of the business. Lagoda Investment Management L.P. grew its stake in shares of VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares during the last quarter. Geode Capital Management LLC lifted its holdings in VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after buying an additional 95,900 shares during the period. Northern Trust Corp grew its position in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after buying an additional 28,579 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of VolitionRx in the fourth quarter valued at about $36,000. Finally, Two Sigma Securities LLC acquired a new stake in shares of VolitionRx in the fourth quarter valued at about $29,000. Institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.